Advertise on podcast: Post-Hoc Live

There isn't a lawmaker on Capitol Hill who's publicly taken a more conservative stance to biopharma's deal spree in China than Rep. John Moolenaar (R-MI), chairman of the House Select Committee on China. He's been the architect of recent legislative proposals that'd clamp down on deals there and also what data regulators can review. So how did this issue rise to his attention? And how committed is he to pressing the issue? Live from Endpoints’ ⁠China Biotech Debate: Washington, DC⁠ ⁠on September 15, 2026.

What do you do when you announce a drug program, then turn around and find out that there are a dozen competitors in China working on the same idea? For many US biotechs, the answer has been to hide their work as long as possible, limiting what they share with the outside world in the hope that it will keep new competitors from emerging (and passing them by). It's a tactic that's been adopted broadly in US biotech, and has led to calls for changes to the patent system. But is it a long-term solution or a short-term fix? And what are the unintended consequences of an R&D and intellectual property system that's less transparent? Live from Endpoints’ ⁠China Biotech Debate: Washington, DC⁠ ⁠on September 15, 2026.

Huge genetic databases. Drug ingredient supply chains. A next pandemic. War with Taiwan. Economic competition. A huge number of topics and scenarios get lumped into the "China biosecurity" conversation — some present and real, some far-fetched and far-off. So what are we really talking about when we talk about China and bio-risk? What deserves the attention and policy action? Which ones are fear-mongering? Live from Endpoints’ ⁠China Biotech Debate: Washington, DC⁠ ⁠on September 15, 2026.

If investment restrictions are the potential consequences to a drug industry that's looked overseas for new assets and early trials, then what's the incentive to come back? The FDA is working to figure it out, and a new agency pilot program is meant to reinvigorate early human research in the US. But is it enough? And is the FDA moving with the urgency that many in the industry say is required? Live from Endpoints’ China Biotech Debate: Washington, DC⁠ on September 15, 2026.

As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? Pfizer's Andrew Baum shares the large drugmaker perspective on acquisitions, R&D, and how the industry could change in the years to come.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.

Should investors embrace China’s fast-moving, fast-growing biotech sector, or should there be barriers to protect and preserve an industry that the US has dominated for decades? Ginkgo Bioworks CEO Jason Kelly, RA Capital Management's Peter Kolchinsky, and MIT professor Fiona Murray debate all sides of the flashpoint issue.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.

In a world where promising drugs are quickly copied, improved on and raced into trials, is science still a differentiator? Strand Therapeutics CEO Jake Becraft and Roivant Sciences CEO Matt Gline discussed what actually counts as innovation, and if where the innovation happens matters for how the industry brings programs to patients. Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.

AstraZeneca and Bristol Myers Squibb are reportedly in talks to combine, which would be one of the largest mergers the biopharma industry has ever seen. What could each company get out of the deal, and what would this deal mean for the industry overall? And are megamergers back? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

Kailera broke records with its $625 million IPO in April. But its high-water mark didn’t last long — in June, Parabalis made a $670 million debut, putting its own name on top of the record books. On Post-Hoc Live, we’re joined by Ron Renaud and Mathai Mammen, the CEOs of the companies, to talk about what it took to reach those heights.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

WuXi is back on the Pentagon’s blacklist. The United States Treasury might restrict investments in Chinese biotech. Despite wave after wave of big pharma announcements around partnerships with China, the protectionist voices are taking up more airtime. Where are the winds blowing, and what material impact could this all have? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

CEO pay keeps going up, and up, and up. What do the pay ratios at pharmas say about the state of the industry as a whole, and how do the eye-popping numbers affect global competition? On Post-Hoc Live, we’ll take you behind the scenes of Endpoints’ annual biopharma compensation report, which breaks down pay for top execs and median workers.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

Jeremy Levin has seen the biopharma industry from practically every vantage point. Now, with decades of experience under his belt, he’s out front in the chorus of veterans sounding the alarm about threats to US dominance in biotech. He joins Post-Hoc Live to talk about China, US policy, and how to stem the bleeding.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

Marty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. The Endpoints and Financial Times teams sat down at the US Pharma and Biotech Summit on Thursday to talk about his tenure, his downfall, and where the FDA goes from here.Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

Thanks to our premium subscribers who joined us live for this special episode of Post-Hoc Live. Catch up on the recording now:Are more deals coming, after a deal-heavy Q1? How are IRA negotiations and MFN deals affecting outlooks? What's the state of the oral weight loss race between Novo and Lilly? We’ll dig into key results and predict what they could mean for the rest of the year.

The CDC hasn’t had a Senate-confirmed director since August. But last week, President Trump announced his next pick — Erica Schwartz, a former deputy surgeon general. She’s a more traditional public-health choice, and if confirmed, faces the formidable tasks of stabilizing the agency and working with RFK Jr., whose anti-vax and MAHA allies have already criticized the pick. We’re joined by Brinda Adhikari, the host of podcast Why Should I Trust You?, to talk about where the CDC and MAHA go from here.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D